Indegene Partners with Datavant to Revolutionize Clinical Trial Recruitment
Indegene Limited has formed a strategic partnership with Datavant to improve patient recruitment for clinical trials, especially for rare diseases and complex studies. The collaboration integrates Datavant's data enrichment capabilities into Indegene's NEXT Patient Recruitment platform. Datavant's network covers over 80,000 hospitals and clinics, processing more than 100 million patient records annually. The partnership aims to streamline participant identification, accelerate trial enrollment, reduce screen failures, and improve screen-to-randomization ratios. This data-driven approach is expected to benefit both patients and pharmaceutical companies by connecting suitable participants with relevant trials more efficiently.
*this image is generated using AI for illustrative purposes only.
Indegene Limited, a digital-first life sciences commercialization company, has announced a strategic partnership with Datavant, a leading healthcare data collaboration platform. This collaboration aims to significantly enhance patient recruitment for clinical trials, with a particular focus on rare diseases and complex studies.
Streamlining Patient Recruitment
The partnership integrates Datavant's data enrichment capabilities into Indegene's NEXT Patient Recruitment platform. This integration is set to address one of the most significant challenges in clinical development: efficient patient recruitment, especially for rare diseases where eligible populations are often small and geographically dispersed.
Leveraging Big Data
Datavant's impressive network spans over 80,000 hospitals and clinics, processing more than 100 million patient records annually. This vast data resource, combined with Indegene's digital-first approach to clinical trial recruitment, promises to streamline the identification of suitable participants based on specific health data criteria.
Benefits for Patients and Pharmaceutical Companies
The collaboration is expected to yield multiple benefits:
- Faster trial enrollment
- Reduced screen failures
- Improved screen-to-randomization ratios
- Accelerated enrollment timelines
For patients, particularly those with rare and complex diseases, this partnership means increased opportunities to connect with trials designed for their specific health conditions.
Industry Perspectives
Arnaub Chatterjee, President and GM of Life Sciences at Datavant, emphasized the partnership's potential impact on rare disease research: "Together with Indegene, we are demonstrating how data enrichment solves that challenge today – and lays the foundation for a new model of clinical research in which sponsors can accelerate recruitment across even the most complex and hard-to-reach populations."
Ram Yeleswarapu, SVP of Enterprise Clinical Solutions at Indegene, highlighted the strategic importance of the partnership: "By integrating secure, real-time access to consented patient medical records into our screening process, we are minimizing one of the greatest challenges in clinical trials – screen failures at sites due to incomplete and ineffective pre-screening."
A Digital-First Approach
This collaboration reinforces Indegene's position as a premier digital-first recruitment partner in the life sciences industry. By leveraging data-driven approaches, the company aims to empower sponsors and sites with solutions that deliver measurable outcomes in clinical trial recruitment and execution.
As the healthcare industry continues to evolve, partnerships like this between Indegene and Datavant demonstrate the growing importance of data-driven solutions in advancing medical research and improving patient outcomes.
Historical Stock Returns for Indegene
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.10% | +2.00% | -0.51% | +9.33% | -8.68% | +2.74% |
19
